← Browse by Condition
Medical Condition

graft vs host disease

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 4
NCT06681922 Phase 1, Phase 2
Recruiting

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Enrollment
10 pts
Location
United States
Sponsor
Northwell Health
View Trial →
NCT06450925 Phase 2
Recruiting

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Enrollment
190 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
View Trial →
NCT06824103 Phase 4
Recruiting

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Enrollment
50 pts
Location
China
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT07184853
Recruiting

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Enrollment
122 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →
NCT04678401 Phase 1
Recruiting

IS-free Treg HaploHCT

Enrollment
30 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →